English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
University Hospital Gasthuisberg
Share :
ESMO 33
12 - 16 Sep 2008
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
4 Dec 2008
Views:
15396
Rating:
Save
Rate video
Prof. Eric Van Cutsem
K-Ras mutations and FOLFIRI plus cetuximab in mCRC.
Categories:
Colorectal & gastro
Related Videos
Immunotherapy significantly increases the number of patients free from bowel...
Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK
14 Jun 2024
Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for...
Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA
2 Jun 2024
Avelumab combined with regorafenib shows improved outcome in solid tumours with...
Prof Antoine Italiano - Institute Bergonié, Bordeaux, France
24 Apr 2024
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...
Dr Lorraine Chantrill - University of Sydney, Sydney, Australia
9 Feb 2024
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...
Prof Hironaga Satake - Kochi Medical School, Kochi, Japan
8 Feb 2024
Combination of cabozantinib and atezolizumab shows moderate activity in...
Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain
30 Jan 2024
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...
Dr Thierry André - Sorbonne Université, Paris, France
24 Jan 2024
Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges
Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria
19 Jan 2024
Colorectal cancer risk factors in Nigeria
Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria
19 Jan 2024
More from
e
cancer